MDCX

+ Watchlist + Portfolio

Medicus Pharma Ltd.

Regulated industry Physical productsTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.16
52-Week Range: $0.14 – $2.78
Market Cap: $11.55M
P/E (TTM): —
EPS (TTM): -2.38
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: -7446.11%
Return on Assets: -110.67%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 1.57
Debt/Equity: —
Total Debt: $21.64M
Free Cash Flow: $-16.16M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $16.67M

MDCX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$646.38K	$193.58K	$3.53M	$16.44M
Selling, General & Admin	$332.03K	$2.46M	$7.65M	$17.92M
Operating Expenses	$978.42K	$2.66M	$11.18M	$34.36M
Operating Income	-$978.42K	-$2.66M	-$11.18M	-$34.36M
EBITDA	-$1.17M	-$2.66M	-$11.18M	-$34.36M
Pretax Income	-$1.69M	-$5.31M	-$11.16M	-$35.44M
Net Income	-$1.69M	-$5.31M	-$11.16M	-$35.44M
Diluted EPS	-0.88	-1.53	-1.16	-2.74
Diluted Shares	8.05M	3.48M	9.62M	17.28M

MDCX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$267.65K	$1.72M	$4.16M	$8.71M
Current Assets	$282.65K	$1.89M	$5.38M	$9.89M
Total Assets	$282.65K	$1.89M	$5.65M	$10.06M
Current Liabilities	$12.48M	$781.61K	$2.31M	$9.94M
Long-Term Debt	—	—	—	$25.86K
Total Debt	$1.53M	$0.00	$322.27K	$5.48M
Total Liabilities	$12.48M	$781.61K	$2.51M	$10.02M
Retained Earnings	-$12.39M	-$17.75M	-$28.90M	-$64.35M
Shareholders' Equity	-$12.20M	$1.11M	$3.13M	-$67.55K
Working Capital	-$12.20M	$1.11M	$3.07M	-$47.42K
Net Debt	$1.26M	—	—	—

MDCX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$1.06M	-$4.16M	-$10.25M	-$22.78M
Free Cash Flow	-$1.06M	-$4.16M	-$10.25M	-$22.78M
Stock-Based Compensation	$0.00	$98.58K	$713.12K	$1.51M
Investing Cash Flow	—	—	$0.00	-$4.62M
Financing Cash Flow	$1.25M	$5.61M	$12.69M	$31.94M
Net Change in Cash	$189.14K	$1.45M	$2.44M	$4.54M

MDCX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$2.01M	$1.44M	$10.40M	$2.59M	$2.70M	$4.91M
Selling, General & Admin	$3.12M	$4.58M	$5.02M	$5.20M	$5.89M	$6.57M
Operating Expenses	$5.13M	$6.02M	$15.43M	$7.79M	$8.60M	$11.48M
Operating Income	-$5.13M	-$6.02M	-$15.43M	-$7.79M	-$8.60M	-$11.48M
EBITDA	-$5.10M	-$6.18M	-$15.43M	-$7.79M	-$8.67M	-$11.48M
Pretax Income	-$5.10M	-$6.18M	-$15.98M	-$8.18M	-$9.04M	-$11.68M
Net Income	-$5.10M	-$6.18M	-$15.98M	-$8.18M	-$9.04M	-$11.62M
Diluted EPS	-0.42	-0.43	-1.12	—	-0.31	-0.21
Diluted Shares	12.24M	14.28M	18.63M	—	29.54M	55.06M

MDCX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$3.98M	$9.67M	$8.66M	$8.71M	$6.37M	$15.17M
Receivables	$14.00K	—	—	—	—	—
Current Assets	$5.09M	$11.00M	$9.78M	$9.89M	$7.28M	$16.98M
Total Assets	$5.66M	$11.93M	$9.98M	$10.06M	$7.43M	$27.12M
Current Liabilities	$3.34M	$8.54M	$10.66M	$9.94M	$5.95M	$10.84M
Long-Term Debt	—	—	$29.46K	$25.86K	$21.04K	$18.00M
Total Debt	$294.69K	$4.97M	$7.05M	$5.48M	$2.53M	$21.64M
Total Liabilities	$3.51M	$8.69M	$10.78M	$10.02M	$6.00M	$28.84M
Retained Earnings	-$34.01M	-$40.18M	-$56.16M	-$64.35M	-$73.39M	-$85.01M
Shareholders' Equity	$2.15M	$3.25M	-$910.13K	-$67.55K	$1.33M	-$1.76M
Working Capital	$1.75M	$2.45M	-$876.49K	-$47.42K	$1.33M	$6.14M
Net Debt	—	—	—	—	—	$6.33M

MDCX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$3.94M	-$5.47M	-$6.76M	-$6.61M	-$8.97M	-$6.98M
Free Cash Flow	-$3.94M	-$5.47M	-$6.76M	-$6.61M	-$8.97M	-$6.98M
Stock-Based Compensation	$112.28K	$117.45K	$852.76K	$429.71K	$599.31K	$1.78M
Investing Cash Flow	—	—	—	$0.00	—	—
Financing Cash Flow	$3.76M	$11.16M	$10.37M	$6.65M	$6.83M	$25.53M
Net Change in Cash	-$181.89K	$5.69M	-$1.01M	$44.35K	-$2.14M	$18.55M

Market Snapshot

About

Medicus Pharma Ltd. is a specialty pharmaceutical company focused on developing and commercializing prescription medicines across various therapeutic areas.